Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis

Company Overview

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.17 to $7.23
• 52-Week Range: N/A
• Volume: 21,870 shs
• Average Volume: 464,030 shs
• Market Capitalization: $450.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IDRA Stock Analysis - Frequently Asked Questions

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01.

When did Idera Pharmaceuticals' stock split?

Idera Pharmaceuticals's stock split before market open on Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly minted shares were issued to shareholders after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What other stocks do shareholders of Idera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Idera Pharmaceuticals investors own include BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Sorrento Therapeutics (SRNE), Proteostasis Therapeutics (PTI), Dynavax Technologies (DVAX), Agenus (AGEN) and SCYNEXIS (SCYX).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IDRA
• CUSIP: N/A
• CIK: 861838
• Web: www.iderapharma.com
• Phone: (484) 348-1600
• Fax: 617-679-5592
• Employees: 32
• Year Founded: 1989

Profitability

• EPS (Most Recent Fiscal Year): ($0.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $98.09 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -68.74%
• Return on Assets: -34.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.56
• Quick Ratio: 1.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 0.29
• Book Value: $0.56 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 62,355,000
• Free Float: 59,206,000
• Market Cap: $450.52 million
• Optionable: Optionable
• Beta: 1.25